The use of reirradiation with intensity-modulated proton therapy yielded strong overall survival with limited toxicity in patients with thoracic tumors, potentially offering a new option in this patient population.
The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.
A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy.
Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.
Men who receive testosterone replacement therapy had an increased rate of favorable-risk prostate cancer compared to those who did not use the therapy, and a decreased rate of aggressive prostate cancer.
The use of sentinel lymph node biopsy alone in women with early cervical cancer resulted in less surgical morbidity without a significant increase in the risk of recurrence, according to a new prospective study.